New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - mepolizumab 100 mg/ml - solution for injection - 100 mg/ml - active: mepolizumab 100 mg/ml excipient: citric acid monohydrate dibasic sodium phosphate heptahydrate disodium edetate polysorbate 80 sucrose water for injection - nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over.

European Union - English - EMA (European Medicines Agency)

bpl bioproducts laboratory gmbh - human coagulation factor x - factor x deficiency - vitamin k and other hemostatics, antihemorrhagics, coagulation factor x - coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor x deficiency. coagadex is indicated in all age groups.

Malta - English - Medicines Authority

abbvie limited citywest business campus, dublin 24, ireland - powder for solution for injection - botulinum toxin type a 100 allergan units/0.1 millilitre - muscle relaxants

Malta - English - Medicines Authority

abbvie limited citywest business campus, dublin 24, ireland - powder for solution for injection - botulinum toxin type a 50 allergan units/0.1 millilitre - muscle relaxants

Malta - English - Medicines Authority

abbvie limited citywest business campus, dublin 24, ireland - powder for solution for injection - botulinum toxin type a 200 allergan units/0.1 millilitre - muscle relaxants

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma limited - cefaclor monohydrate - prolonged-release tablet - 375 milligram(s) - second-generation cephalosporins; cefaclor

Ireland - English - HPRA (Health Products Regulatory Authority)

flynn pharma limited - cefaclor monohydrate - prolonged-release tablet - 500 milligram(s) - second-generation cephalosporins; cefaclor

Ireland - English - HPRA (Health Products Regulatory Authority)

hikma farmacêutica (portugal) s.a. - imipenem; cilastatin - powder for solution for infusion - 500 mg/500 milligram(s) - carbapenems; imipenem and enzyme inhibitor

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - cilastatin sodium; imipenem monohydrate - powder for solution for infusion - 500mg ; 500mg

European Union - English - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - meropenem trihydrate, vaborbactam - urinary tract infections; bacteremia; bacterial infections; respiratory tract infections; pneumonia; pneumonia, ventilator-associated - antibacterials for systemic use, - vaborem is indicated for the treatment of the following infections in adults:complicated urinary tract infection (cuti), including pyelonephritiscomplicated intra-abdominal infection (ciai)hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap).treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.vaborem is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options.consideration should be given to official guidance on the appropriate use of antibacterial agents.